Figure 2 (IMAGE)

Hong Kong University of Science and Technology

Figure 2

Caption

A joint research team from The Hong Kong University of Science and Technology (HKUST), and the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) have demonstrated that ZCB11, a broadly neutralising antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2. The research team members include (from left): Professor Dang Shangyu, Assistant Professor of Division of Life Science, HKUST and Professor Chen Zhiwei, Director of AIDS Institute of the University of Hong Kong and Professor of the Department of Microbiology, School of Clinical Medicine, HKUMed.

Credit

HKUST

Usage Restrictions

NA

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.